Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irbesartan + amlodipine
- Development stage
- Phase 3
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Irbesartan + amlodipine** is an oral fixed-dose antihypertensive combination of two small molecules: irbesartan, a selective angiotensin II type 1 receptor blocker, and amlodipine, a dihydropyridine calcium-channel blocker. Dual inhibition of angiotensin II-mediated vasoconstriction and L-type calcium-channel-mediated vascular smooth-muscle contraction lowers systemic blood pressure. It is marketed in multiple countries as fixed-dose tablets, including Aprovasc and ILUAMIX, for essential hypertension inadequately controlled with either component alone or for patients transitioning from the two agents given separately. ([campus.sanofi](https://www.campus.sanofi/dam/jcr%3A7dd59183-3914-4cfd-99cc-c9a6fec06e00/Aprovasc%20IQ%20SmPC.pdf))
- Brand names
- AimixAizecusAprovascILUAMIX
- Other names
- amlodipine + irbesartanirbesartan and amlodipineirbesartan/amlodipine
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on irbesartan + amlodipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irbesartan + amlodipine.